Fenbufen
产品说明书
 |
同义名 : | 3-(4-联苯羰基)丙酸 ;CL-82204; Lederfen; Cinopal |
| CAS号 : | 36330-85-5 | |
| 货号 : | A819665 | |
| 分子式 : | C16H14O3 | |
| 纯度 : | 99% | |
| 分子量 : | 254.281 | |
| MDL号 : | MFCD00056701 | |
| 存储条件： |
Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(196.63 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Fenbufen is a non-selective non-steroidal anti-inflammatory drug (NSAID), used to treat acute and chronic painful conditions. Fenbufen at both doses (800 mg or 400 mg, oral) had apparent analgesic efficacy[3]. Fenbufen is a phenylalkanoic acid derivative with analgesic and anti-inflammatory activity. At a daily dosage of 600 mg, fenbufen is comparable with aspirin 3.6 g or indomethacin 75 mg in osteoarthritis[4]. Like clinically used nonsteroidal anti-inflammatory drugs, Fenbufen shows activity in a wide spectrum of laboratory tests in mice, rats, guinea pigs, and dogs. Fenbufen has a long duration of anti-inflammatory and analgesic activity. Mechanistic studies indicate that fenbufen has no intrinsic effect on cyclooxygenase activity, whereas its major metabolite, biphenylacetic acid, is a potent inhibitor of prostaglandin synthesis. Comparative studies in the type II collagen arthritis model indicate that the anti-inflammatory properties of fenbufen are more potent than those of a second nonsteroidal anti-inflammatory drug, sulindac[5]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.93mL 0.79mL 0.39mL |
19.66mL 3.93mL 1.97mL |
39.33mL 7.87mL 3.93mL |
| 参考文献 |
|---|
|
[5]Kerwar SS. Pharmacologic properties of fenbufen. Am J Med. 1983 Oct 31;75(4B):62-9 |